Scarica l'app Stockscreener
0.90
9.09%
-0.09
Dopo l'orario di chiusura:
.93
0.03
+3.33%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Unity Biotechnology Inc Borsa (UBX) Ultime notizie
Unity Biotechnology stock hits 52-week low at $0.94 - Investing.com
Unity Biotechnology CFO Lynne Sullivan sells $22,523 in stock - Investing.com
Unity Biotechnology Executives Sell Shares for Tax Obligations - TradingView
What is HC Wainwright’s Estimate for UBX FY2026 Earnings? - Defense World
Unity Biotechnology (NASDAQ:UBX) Price Target Lowered to $4.00 at Chardan Capital - Defense World
H.C. Wainwright cuts Unity Biotechnology target to $4; keeps buy rating - Investing.com Australia
UBX Stock Down 29% on Mixed Results From Phase II Eye Disease Study - MSN
Unity Biotechnology price target lowered to $4 from $6 at Chardan - TipRanks
H.C. Wainwright cuts Unity Biotechnology target to $4; keeps buy rating By Investing.com - Investing.com South Africa
UNITY Biotechnology tanks on mixed results for eye disease drug - The Pharma Letter
Mizuho maintains Unity Biotechnology Outperform rating By Investing.com - Investing.com South Africa
Chardan Cuts Price Target on Unity Biotechnology to $4 From $6, Keeps Buy Rating - Marketscreener.com
Mizuho maintains Unity Biotechnology Outperform rating - Investing.com India
Unity Biotechnology (NASDAQ:UBX) Price Target Cut to $4.00 by Analysts at HC Wainwright - Defense World
UNITY Biotechnology to Host Virtual Investor Event to Discuss 24- and 36-Week Data from the Phase 2b ASPIRE - EIN News
Sector Update: Health Care Stocks Rise Late Afternoon - TradingView
Sector Update: Health Care - TradingView
Unity Biotechnology Shares Decline After Diabetic Edema Treatment Misses Primary Endpoint - Marketscreener.com
UNITY Biotechnology tanks after failing to meet goal in eye disorder treatment trial - MSN
HC Wainwright Adjusts Unity Biotechnology Price Target to $4 From $8, Maintains Buy Rating - Marketscreener.com
UNITY Biotechnology Shares Drop 33% After Phase 2b Trial Data on UBX1325 in Diabetic Macular Edema - Yahoo Finance
Unity Biotechnology Unveils Mixed Data From Study For Diabetes-Related Blindness, Stock Falls - Benzinga
Unity Biotechnology, Inc. Announces Topline Results from the ASPIRE Phase 2B Study in Diabetic Macular Edema - MarketScreener
UNITY Biotechnology Announces Topline Results from the ASPIRE Phase 2b Study in Diabetic Macular Edema - GlobeNewswire
New DME Treatment Matches Standard Care: Phase 2b Shows Promising Vision Gains - Stock Titan
China’s Plans for a $900 Billion Space Project, but Can It Catch Up to SpaceX? - The Globe and Mail
UNITY Biotechnology to Host Virtual Investor Event Featuring Phase 2b ASPIRE Study Results for UBX1325 in Diabetic Macular Edema - Nasdaq
UNITY Biotechnology to Host Virtual Investor Event to - GlobeNewswire
Key Phase 2b Data Coming: UNITY's DME Treatment Could Transform Eye Disease Care - Stock Titan
Where Will QuantumScape Stock Be in 3 Years? - The Globe and Mail
This Micro Cap Continues This Week's Dominance Amid New CEO Appointment - The Globe and Mail
RECONAFRICA ANNOUNCES ACCELERATION OF DRILLING INTO Q2 2025 AND A CORPORATE UPDATE - The Globe and Mail
3 Reasons to Avoid AIR and 1 Stock to Buy Instead - The Globe and Mail
This Media Stock Is Finding Serious Success Prior To Opening Bell - The Globe and Mail
Unity Biotechnology Reports 2024 Financial Results and Updates - MSN
Unity Biotechnology announces upcoming trial data and new board of directors member - Ophthalmology Times
Chardan Capital Has Bullish Outlook for UBX FY2025 Earnings - Defense World
HC Wainwright Has Strong Estimate for UBX FY2025 Earnings - Defense World
Analysts Issue Forecasts for UBX Q1 Earnings - Defense World
Unity Biotechnology (NASDAQ:UBX) Receives “Buy” Rating from Chardan Capital - Defense World
UNITY Biotechnology appoints Yehia Hashad to its board -March 10, 2025 at 10:40 am EDT - Marketscreener.com
Unity Biotechnology Appoints Dr. Yehia Hashad to Board - TipRanks
UNITY Biotechnology Appoints Industry Leader and - GlobeNewswire
UNITY Biotech Strengthens Board with CMO Appointment Before Key Trial Results - StockTitan
Buy Rating Reaffirmed for Unity Biotechnology Amid Promising Developments in DME Treatment - TipRanks
Unity Biotechnology reports Q4 EPS (50c) vs. (28c) last year - TipRanks
UNITY Biotechnology Reports Q4 and Full Year 2024 Financial Results and Anticipates ASPIRE Study Data on UBX1325 for Diabetic Macular Edema - Nasdaq
Unity Biotechnology, Inc. SEC 10-K Report - TradingView
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates - GlobeNewswire
10.70%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):